Jefferies Financial Group Inc. Buys Shares of 8,234 Lantheus Holdings, Inc. $LNTH

Jefferies Financial Group Inc. bought a new stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 8,234 shares of the medical equipment provider’s stock, valued at approximately $913,000.

Several other large investors have also made changes to their positions in LNTH. ABS Investment Management LLC acquired a new position in Lantheus during the second quarter valued at approximately $232,974,000. Versant Capital Management Inc lifted its position in shares of Lantheus by 33.0% during the 2nd quarter. Versant Capital Management Inc now owns 588 shares of the medical equipment provider’s stock worth $65,000 after buying an additional 146 shares during the last quarter. Abel Hall LLC lifted its position in shares of Lantheus by 4.6% during the 1st quarter. Abel Hall LLC now owns 3,915 shares of the medical equipment provider’s stock worth $297,000 after buying an additional 172 shares during the last quarter. Smartleaf Asset Management LLC boosted its stake in Lantheus by 63.3% in the fourth quarter. Smartleaf Asset Management LLC now owns 508 shares of the medical equipment provider’s stock valued at $34,000 after buying an additional 197 shares in the last quarter. Finally, GAMMA Investing LLC grew its position in Lantheus by 6.4% in the second quarter. GAMMA Investing LLC now owns 3,348 shares of the medical equipment provider’s stock valued at $371,000 after acquiring an additional 202 shares during the last quarter. Institutional investors and hedge funds own 99.06% of the company’s stock.

Analyst Ratings Changes

Several research analysts have commented on LNTH shares. Wall Street Zen downgraded Lantheus from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 9th. CJS Securities cut shares of Lantheus from a “market outperform” rating to a “market perform” rating in a research report on Tuesday, August 4th. Truist Financial downgraded shares of Lantheus from a “buy” rating to a “hold” rating and dropped their price objective for the company from $125.00 to $102.50 in a research note on Monday, August 3rd. TD Cowen lowered shares of Lantheus from a “buy” rating to a “hold” rating and cut their target price for the company from $110.00 to $102.50 in a research report on Monday, August 3rd. Finally, Leerink Partners set a $102.50 price target on shares of Lantheus in a report on Monday, August 3rd. Four investment analysts have rated the stock with a Buy rating and ten have given a Hold rating to the stock. Based on data from MarketBeat, Lantheus has a consensus rating of “Hold” and an average target price of $108.11.

Lantheus Stock Performance

Lantheus stock opened at $100.77 on Monday. The business has a 50 day moving average of $103.74 and a 200-day moving average of $91.76. The company has a market capitalization of $6.58 billion, a P/E ratio of 24.34 and a beta of -0.03. Lantheus Holdings, Inc. has a 1 year low of $49.67 and a 1 year high of $111.86. The company has a debt-to-equity ratio of 0.43, a current ratio of 3.06 and a quick ratio of 2.89.

Lantheus (NASDAQ:LNTH) last posted its earnings results on Thursday, August 6th. The medical equipment provider reported $1.55 EPS for the quarter, topping the consensus estimate of $1.30 by $0.25. The business had revenue of $388.18 million for the quarter, compared to the consensus estimate of $363.23 million. Lantheus had a net margin of 17.69% and a return on equity of 28.10%. The firm’s revenue was up 2.7% compared to the same quarter last year. During the same period last year, the company earned $1.57 EPS. On average, equities research analysts predict that Lantheus Holdings, Inc. will post 4.48 earnings per share for the current year.

Lantheus Company Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.